Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

Immunity

Volumn 48, Issue 3, 2018, Pages 417-433

  Patel, Shetal A ^a,b   Minn, Andy J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTIGENICITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG MECHANISM; EPIGENETICS; GENOTOXICITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MOLECULARLY TARGETED THERAPY; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; ANIMAL; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85043766913     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2018.03.007     Document Type: Review

References (170)

1. + T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47 (2017), 848–861.e5.
2. Andreeva, L., Hiller, B., Kostrewa, D., Lässig, C., de Oliveira Mann, C.C., Jan Drexler, D., Maiser, A., Gaidt, M., Leonhardt, H., Hornung, V., Hopfner, K.-P., cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders. Nature 549 (2017), 394–398.
3. Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K.H., de Wit, M., et al., PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377 (2017), 1919–1929.
4. Arce Vargas, F., Furness, A.J.S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. Melanoma TRACERx Consortium Renal TRACERx Consortium, Lung TRACERx Consortium. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46 (2017), 577–586.
5. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B., Palucka, K., Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000), 767–811.
6. Baumeister, S.H., Freeman, G.J., Dranoff, G., Sharpe, A.H., Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34 (2016), 539–573.
7. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D.S.M., Pauken, K.E., Huang, A.C., et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167 (2016), 1540–1554.e12.
8. Bernard, J.J., Cowing-Zitron, C., Nakatsuji, T., Muehleisen, B., Muto, J., Borkowski, A.W., Martinez, L., Greidinger, E.L., Yu, B.D., Gallo, R.L., Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med. 18 (2012), 1286–1290.
9. Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A.A., Wherry, E.J., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
10. Bonam, S.R., Partidos, C.D., Halmuthur, S.K.M., Muller, S., An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol. Sci. 38 (2017), 771–793.
11. Byrne, K.T., Vonderheide, R.H., CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15 (2016), 2719–2732.
12. Cekic, C., Linden, J., Purinergic regulation of the immune system. Nat. Rev. Immunol. 16 (2016), 177–192.
13. Charlebois, R., Allard, B., Allard, D., Buisseret, L., Turcotte, M., Pommey, S., Chrobak, P., Stagg, J., PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors. Cancer Res. 77 (2017), 312–319.
14. Chen, L., Guo, S., Ranzer, M.J., DiPietro, L.A., Toll-like receptor 4 has an essential role in early skin wound healing. J. Invest. Dermatol. 133 (2013), 258–267.
15. Chen, L., Gibbons, D.L., Goswami, S., Cortez, M.A., Ahn, Y.H., Byers, L.A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun., 5, 2014, 5241.
16. Chen, Q., Sun, L., Chen, Z.J., Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17 (2016), 1142–1149.
17. Chiang, J.J., Sparrer, K.M.J., van Gent, M., Lässig, C., Huang, T., Osterrieder, N., Hopfner, K.-P., Gack, M.U., Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity. Nat. Immunol. 19 (2018), 53–62.
18. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N.S., Cope, L.M., Snyder, A., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162 (2015), 974–986.
19. Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N.J.M., Ciampricotti, M., Hawinkels, L.J.A.C., Jonkers, J., de Visser, K.E., IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522 (2015), 345–348.
20. Corrales, L., Glickman, L.H., McWhirter, S.M., Kanne, D.B., Sivick, K.E., Katibah, G.E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J.J., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11 (2015), 1018–1030.
21. Coussens, L.M., Zitvogel, L., Palucka, A.K., Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339 (2013), 286–291.
22. Crouse, J., Kalinke, U., Oxenius, A., Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 15 (2015), 231–242.
23. Cubillos-Ruiz, J.R., Silberman, P.C., Rutkowski, M.R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S.E., Gupta, D., Holcomb, K., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161 (2015), 1527–1538.
24. De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539 (2016), 443–447.
25. DeKruyff, R.H., Bu, X., Ballesteros, A., Santiago, C., Chim, Y.-L.E., Lee, H.-H., Karisola, P., Pichavant, M., Kaplan, G.G., Umetsu, D.T., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184 (2010), 1918–1930.
26. Demaria, S., Kawashima, N., Yang, A.M., Devitt, M.L., Babb, J.S., Allison, J.P., Formenti, S.C., Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11 (2005), 728–734.
27. Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1 (2015), 1325–1332.
28. Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852.
29. Deng, J., Wang, E.S., Jenkins, R.W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A.R., et al. CDK4/6 inhibition augments anti-tumor immunity by enhancing T cell activation. Cancer Discov. 8 (2017), 216–233.
30. Devarkar, S.C., Wang, C., Miller, M.T., Ramanathan, A., Jiang, F., Khan, A.G., Patel, S.S., Marcotrigiano, J., Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. Proc. Natl. Acad. Sci. USA 113 (2016), 596–601.
31. Dighe, A.S., Richards, E., Old, L.J., Schreiber, R.D., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1 (1994), 447–456.
32. Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H.L., Weinberg, R.A., Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77 (2017), 3982–3989.
33. Dou, Z., Ghosh, K., Vizioli, M.G., Zhu, J., Sen, P., Wangensteen, K.J., Simithy, J., Lan, Y., Lin, Y., Zhou, Z., et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550 (2017), 402–406.
34. DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., Jacks, T., Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482 (2012), 405–409.
35. Enyedi, B., Niethammer, P., Mechanisms of epithelial wound detection. Trends Cell Biol. 25 (2015), 398–407.
36. Fu, G., Rybakin, V., Brzostek, J., Paster, W., Acuto, O., Gascoigne, N.R.J., Fine-tuning T cell receptor signaling to control T cell development. Trends Immunol. 35 (2014), 311–318.
37. Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., Mechette, K., Leong, J.J., Lauer, P., Liu, W., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med., 7, 2015, 283ra52.
38. Galluzzi, L., Buqué A., Kepp, O., Zitvogel, L., Kroemer, G., Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28 (2015), 690–714.
39. Galluzzi, L., Buqué A., Kepp, O., Zitvogel, L., Kroemer, G., Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17 (2017), 97–111.
40. Gamrekelashvili, J., Ormandy, L.A., Heimesaat, M.M., Kirschning, C.J., Manns, M.P., Korangy, F., Greten, T.F., Primary sterile necrotic cells fail to cross-prime CD8(+) T cells. OncoImmunology 1 (2012), 1017–1026.
41. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404.e9.
42. Garg, A.D., More, S., Rufo, N., Mece, O., Sassano, M.L., Agostinis, P., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 6, 2017, e1386829.
43. Gerner, M.Y., Heltemes-Harris, L.M., Fife, B.T., Mescher, M.F., Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191 (2013), 1011–1015.
44. Ghoneim, H.E., Fan, Y., Moustaki, A., Abdelsamed, H.A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P.G., Youngblood, B., De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170 (2017), 142–157.e19.
45. Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O'Donnell, J.S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity 47 (2017), 789–802.e9.
46. Glück, S., Guey, B., Gulen, M.F., Wolter, K., Kang, T.-W., Schmacke, N.A., Bridgeman, A., Rehwinkel, J., Zender, L., Ablasser, A., Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat. Cell Biol. 19 (2017), 1061–1070.
47. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548 (2017), 471–475.
48. Green, D.R., Ferguson, T., Zitvogel, L., Kroemer, G., Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9 (2009), 353–363.
49. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124 (2014), 2246–2259.
50. Guerriero, J.L., Sotayo, A., Ponichtera, H.E., Castrillon, J.A., Pourzia, A.L., Schad, S., Johnson, S.F., Carrasco, R.D., Lazo, S., Bronson, R.T., et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543 (2017), 428–432.
51. Hamilton, D.H., Huang, B., Fernando, R.I., Tsang, K.-Y., Palena, C., WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Res. 74 (2014), 2510–2519.
52. Harding, S.M., Benci, J.L., Irianto, J., Discher, D.E., Minn, A.J., Greenberg, R.A., Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548 (2017), 466–470.
53. Härtlova, A., Erttmann, S.F., Raffi, F.A., Schmalz, A.M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L.M., Kröger, A., Nilsson, J.A., et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42 (2015), 332–343.
54. He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature 537 (2016), 412–428.
55. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
56. Hirano, T., Ishihara, K., Hibi, M., Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19 (2000), 2548–2556.
57. Hochheiser, K., Klein, M., Gottschalk, C., Hoss, F., Scheu, S., Coch, C., Hartmann, G., Kurts, C., Cutting edge: The RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination. J. Immunol. 196 (2016), 2439–2443.
58. Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
59. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
60. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
61. Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M.J., Wallweber, H.A., Sasmal, D.K., Huang, J., Kim, J.M., Mellman, I., Vale, R.D., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355 (2017), 1428–1433.
62. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
63. Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat. Immunol. 16 (2015), 343–353.
64. Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H.A., Gill, M.B., Park, K.J., Zivanovic, O., Konner, J., et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170 (2017), 927–938.e20.
65. Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1 (2011), 598–607.
66. Kamphorst, A.O., Pillai, R.N., Yang, S., Nasti, T.H., Akondy, R.S., Wieland, A., Sica, G.L., Yu, K., Koenig, L., Patel, N.T., et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114 (2017), 4993–4998.
67. Kamphorst, A.O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D.L., Konieczny, B.T., Daugherty, C.Z., Koenig, L., Yu, K., et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355 (2017), 1423–1427.
68. Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., Woo, G., Nguyen, A.V., Figueiredo, C.C., Foubert, P., et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539 (2016), 437–442.
69. Katlinski, K.V., Gui, J., Katlinskaya, Y.V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C.J., Beiting, D.P., Girondo, M.A., Peck, A.R., et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31 (2017), 194–207.
70. Kohlhapp, F.J., Kaufman, H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 22 (2016), 1048–1054.
71. Kortlever, R.M., Sodir, N.M., Wilson, C.H., Burkhart, D.L., Pellegrinet, L., Brown Swigart, L., Littlewood, T.D., Evan, G.I., Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171 (2017), 1301–1315.e14.
72. Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., Asahina, H., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 7, 2016, 10501.
73. Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
74. Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., Gentzler, R.D., Martins, R.G., Stevenson, J.P., Jalal, S.I., et al., KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17 (2016), 1497–1508.
75. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
76. Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114 (2009), 589–595.
77. Lim, W.A., June, C.H., The Principles of engineering immune cells to treat cancer. Cell 168 (2017), 724–740.
78. Lin, Q., Fang, D., Fang, J., Ren, X., Yang, X., Wen, F., Su, S.B., Impaired wound healing with defective expression of chemokines and recruitment of myeloid cells in TLR3-deficient mice. J. Immunol. 186 (2011), 3710–3717.
79. Lin, Q., Wang, L., Lin, Y., Liu, X., Ren, X., Wen, S., Du, X., Lu, T., Su, S.Y., Yang, X., et al. Toll-like receptor 3 ligand polyinosinic:polycytidylic acid promotes wound healing in human and murine skin. J. Invest. Dermatol. 132 (2012), 2085–2092.
80. Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A.A., Schenk, A.D., Miller, H.E., Guleria, I., Barth, R.J., Huang, Y.H., Wang, L., Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl. Acad. Sci. USA 112 (2015), 6682–6687.
81. Lou, Y., Diao, L., Cuentas, E.R.P., Denning, W.L., Chen, L., Fan, Y.H., Byers, L.A., Wang, J., Papadimitrakopoulou, V.A., Behrens, C., et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 3630–3642.
82. Mackenzie, K.J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D.J., Olova, N., Sutcliffe, H., Rainger, J.K., Leitch, A., et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548 (2017), 461–465.
83. Mak, M.P., Tong, P., Diao, L., Cardnell, R.J., Gibbons, D.L., William, W.N., Skoulidis, F., Parra, E.R., Rodriguez-Canales, J., Wistuba, I.I., et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res. 22 (2016), 609–620.
84. Manguso, R.T., Pope, H.W., Zimmer, M.D., Brown, F.D., Yates, K.B., Miller, B.C., Collins, N.B., Bi, K., LaFleur, M.W., Juneja, V.R., et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547 (2017), 413–418.
85. Marcucci, F., Stassi, G., De Maria, R., Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat. Rev. Drug Discov. 15 (2016), 311–325.
86. Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel Iii, E.E., Koeppen, H., Astarita, J.L., Cubas, R., et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554 (2018), 544–548.
87. Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.-S., Shea, L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
88. McGranahan, N., Furness, A.J.S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
89. Minn, A.J., Wherry, E.J., Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165 (2016), 272–275.
90. Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M.V., Qin, J., Carson, D.A., Guan, K.-L., The hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 167 (2016), 1525–1539.e17.
91. Muraro, E., Furlan, C., Avanzo, M., Martorelli, D., Comaro, E., Rizzo, A., Fae’ D.A., Berretta, M., Militello, L., Del Conte, A., et al. Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. Front. Immunol., 8, 2017, 1476.
92. Nabet, B.Y., Qiu, Y., Shabason, J.E., Wu, T.J., Yoon, T., Kim, B.C., Benci, J.L., DeMichele, A.M., Tchou, J., Marcotrigiano, J., Minn, A.J., Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell 170 (2017), 352–366.e13.
93. Ng, C.T., Sullivan, B.M., Teijaro, J.R., Lee, A.M., Welch, M., Rice, S., Sheehan, K.C.F., Schreiber, R.D., Oldstone, M.B.A., Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17 (2015), 653–661.
94. Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18 (2010), 160–170.
95. Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36 (2015), 265–276.
96. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
97. Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
98. Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44 (2016), 343–354.
99. Philip, M., Fairchild, L., Sun, L., Horste, E.L., Camara, S., Shakiba, M., Scott, A.C., Viale, A., Lauer, P., Merghoub, T., et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545 (2017), 452–456.
100. Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S.S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14 (2008), 1256–1263.
101. Portou, M.J., Baker, D., Abraham, D., Tsui, J., The innate immune system, toll-like receptors and dermal wound healing: A review. Vascul. Pharmacol. 71 (2015), 31–36.
102. Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366 (2012), 925–931.
103. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
104. Prendergast, G.C., Malachowski, W.P., DuHadaway, J.B., Muller, A.J., Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 77 (2017), 6795–6811.
105. Purbey, P.K., Scumpia, P.O., Kim, P.J., Tong, A.-J., Iwamoto, K.S., McBride, W.H., Smale, S.T., Defined sensing mechanisms and signaling pathways contribute to the global inflammatory gene expression output elicited by ionizing radiation. Immunity 47 (2017), 421–434.e3.
106. Ranoa, D.R.E., Parekh, A.D., Pitroda, S.P., Huang, X., Darga, T., Wong, A.C., Huang, L., Andrade, J., Staley, J.P., Satoh, T., et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7 (2016), 26496–26515.
107. Reiman, J.M., Knutson, K.L., Radisky, D.C., Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 70 (2010), 3005–3008.
108. Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., de Ru, A.H., Neijssen, J., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203 (2006), 1259–1271.
109. Riaz, N., Havel, J.J., Makarov, V., Desrichard, A., Urba, W.J., Sims, J.S., Hodi, F.S., Martín-Algarra, S., Mandal, R., Sharfman, W.H., et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171 (2017), 934–949.e15.
110. Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R.H.I., Michielin, O., Olszanski, A.J., Malvehy, J., Cebon, J., Fernandez, E., et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170 (2017), 1109–1119.e10.
111. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
112. Rongvaux, A., Jackson, R., Harman, C.C.D., Li, T., West, A.P., de Zoete, M.R., Wu, Y., Yordy, B., Lakhani, S.A., Kuan, C.-Y., et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell 159 (2014), 1563–1577.
113. Rotow, J., Bivona, T.G., Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 17 (2017), 637–658.
114. Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S.Y., Han, H., Liang, G., Jones, P.A., Pugh, T.J., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162 (2015), 961–973.
115. Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M.T., Pryer, N., Daniel, D., Hwang, E.S., Rugo, H.S., Coussens, L.M., Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
116. Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 (2010), 2187–2194.
117. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
118. Sandler, N.G., Bosinger, S.E., Estes, J.D., Zhu, R.T.R., Tharp, G.K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K.N., del Prete, G.Q., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511 (2014), 601–605.
119. Sanmamed, M.F., Pastor, F., Rodriguez, A., Perez-Gracia, J.L., Rodriguez-Ruiz, M.E., Jure-Kunkel, M., Melero, I., Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42 (2015), 640–655.
120. Sato, T., Yamamoto, M., Shimosato, T., Klinman, D.M., Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen. 18 (2010), 586–593.
121. Schietinger, A., Philip, M., Krisnawan, V.E., Chiu, E.Y., Delrow, J.J., Basom, R.S., Lauer, P., Brockstedt, D.G., Knoblaugh, S.E., Hämmerling, G.J., et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45 (2016), 389–401.
122. Schlee, M., Hartmann, G., Discriminating self from non-self in nucleic acid sensing. Nat. Rev. Immunol. 16 (2016), 566–580.
123. Schuberth-Wagner, C., Ludwig, J., Bruder, A.K., Herzner, A.-M., Zillinger, T., Goldeck, M., Schmidt, T., Schmid-Burgk, J.L., Kerber, R., Wolter, S., et al. A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-2’O-methylated self RNA. Immunity 43 (2015), 41–51.
124. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
125. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.-W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
126. Shabason, J.E., Minn, A.J., Radiation and immune checkpoint blockade: from bench to clinic. Semin. Radiat. Oncol. 27 (2017), 289–298.
127. Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M.C., Depil, S., Caux, C., Marabelle, A., Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28 (2017), 1756–1766.
128. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 171 (2017), 1221–1223.
129. Sistigu, A., Di Modugno, F., Manic, G., Nisticò P., Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine Growth Factor Rev. 36 (2017), 67–77.
130. Snell, L.M., Brooks, D.G., New insights into type I interferon and the immunopathogenesis of persistent viral infections. Curr. Opin. Immunol. 34 (2015), 91–98.
131. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
132. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200ra116.
133. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
134. Spranger, S., Dai, D., Horton, B., Gajewski, T.F., Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31 (2017), 711–723.e4.
135. Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., Teng, M.W., Smyth, M.J., Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108 (2011), 7142–7147.
136. Stelekati, E., Shin, H., Doering, T.A., Dolfi, D.V., Ziegler, C.G., Beiting, D.P., Dawson, L., Liboon, J., Wolski, D., Ali, M.-A.A., et al. Bystander chronic infection negatively impacts development of CD8(+) T cell memory. Immunity 40 (2014), 801–813.
137. Suga, H., Sugaya, M., Fujita, H., Asano, Y., Tada, Y., Kadono, T., Sato, S., TLR4, rather than TLR2, regulates wound healing through TGF-β and CCL5 expression. J. Dermatol. Sci. 73 (2014), 117–124.
138. Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
139. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., Chen, L., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4, 2012, 127ra37.
140. Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
141. Tauriello, D.V.F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554 (2018), 538–543.
142. Teijaro, J.R., Ng, C., Lee, A.M., Sullivan, B.M., Sheehan, K.C.F., Welch, M., Schreiber, R.D., de la Torre, J.C., Oldstone, M.B.A., Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340 (2013), 207–211.
143. Thiery, J.P., Acloque, H., Huang, R.Y.J., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
144. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
145. Topper, M.J., Vaz, M., Chiappinelli, K.B., DeStefano Shields, C.E., Niknafs, N., Yen, R.C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171 (2017), 1284–1300.e21.
146. Trahtemberg, U., Mevorach, D., Apoptotic cells induced signaling for immune homeostasis in macrophages and dendritic cells. Front. Immunol., 8, 2017, 1356.
147. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
148. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
149. Urban, S.L., Welsh, R.M., Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses. PLoS Pathog., 10, 2014, e1004357.
150. Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45 (2016), 415–427.
151. Vacchelli, E., Ma, Y., Baracco, E.E., Sistigu, A., Enot, D.P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350 (2015), 972–978.
152. van den Broek, M.F., Müller, U., Huang, S., Aguet, M., Zinkernagel, R.M., Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69 (1995), 4792–4796.
153. van den Broek, M.F., Müller, U., Huang, S., Zinkernagel, R.M., Aguet, M., Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148 (1995), 5–18.
154. Vanpouille-Box, C., Diamond, J.M., Pilones, K.A., Zavadil, J., Babb, J.S., Formenti, S.C., Barcellos-Hoff, M.H., Demaria, S., TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75 (2015), 2232–2242.
155. Vanpouille-Box, C., Alard, A., Aryankalayil, M.J., Sarfraz, Y., Diamond, J.M., Schneider, R.J., Inghirami, G., Coleman, C.N., Formenti, S.C., Demaria, S., DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun., 8, 2017, 15618.
156. Wang, L., Rubinstein, R., Lines, J.L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.F., Gondek, D., Wang, Y., Fava, R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208 (2011), 577–592.
157. Wang, Y., Swiecki, M., Cella, M., Alber, G., Schreiber, R.D., Gilfillan, S., Colonna, M., Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11 (2012), 631–642.
158. Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., Chen, Z.J., cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl. Acad. Sci. USA 114 (2017), 1637–1642.
159. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.e17.
160. Wellenstein, M.D., de Visser, K.E., Cancer cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48 (2018), 399–416 this issue.
161. White, M.J., McArthur, K., Metcalf, D., Lane, R.M., Cambier, J.C., Herold, M.J., van Delft, M.F., Bedoui, S., Lessene, G., Ritchie, M.E., et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159 (2014), 1549–1562.
162. Wilson, E.B., Yamada, D.H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B.J., Karp, C.L., Brooks, D.G., Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340 (2013), 202–207.
163. Woo, S.-R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y.K., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
164. Xia, T., Konno, H., Ahn, J., Barber, G.N., Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14 (2016), 282–297.
165. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
166. Zhang, T., Yu, H., Ni, C., Zhang, T., Liu, L., Lv, Q., Zhang, Z., Wang, Z., Wu, D., Wu, P., et al. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci. Rep., 7, 2017, 4866.
167. Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N.T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553 (2018), 91–95.
168. Zhu, Y., Knolhoff, B.L., Meyer, M.A., Nywening, T.M., West, B.L., Luo, J., Wang-Gillam, A., Goedegebuure, S.P., Linehan, D.C., DeNardo, D.G., CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74 (2014), 5057–5069.
169. Zhu, J., Powis de Tenbossche, C.G., Cané S., Colau, D., van Baren, N., Lurquin, C., Schmitt-Verhulst, A.-M., Liljeström, P., Uyttenhove, C., Van den Eynde, B.J., Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat. Commun., 8, 2017, 1404.
170. Zuniga, E.I., Harker, J.A., T-cell exhaustion due to persistent antigen: quantity not quality?. Eur. J. Immunol. 42 (2012), 2285–2289.